4.7 Article

Doxorubicin loading fucoidan acetate nanoparticles for immune and chemotherapy in cancer treatment

Journal

CARBOHYDRATE POLYMERS
Volume 94, Issue 2, Pages 850-856

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2013.02.018

Keywords

Immuno-chemotherapy; Acetylated fucoidan; Anti-tumor cytokines; Multidrug resistance

Funding

  1. Korean Ministry of Education, Science and Technology through Strategic Research [2011-0028726]

Ask authors/readers for more resources

In order to develop immuno- and chemotherapy agents, self-organized acetylated fucoidan (AcFu) nanoparticles were designed. Doxorubicin (DOX), used as a model drug, was loaded into the AcFu nanoparticles by dialysis. The DOX loading efficacy and content were 71.1% and 3.6%, respectively. Approximately 140 nm of spherical nanoparticles were obtained. DOX-loaded AcFu nanoparticles (DOX-AcFu) exhibited first-order drug release behavior for 5 days. Interestingly, AcFu treated Raw264.7 macrophages overexpressed various anti-tumor cytokines, such as tumor necrosis factor-alpha (TNF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF). The ability of DOX-AcFu to suppress drug efflux was revealed by confocal microscope images and FACS analysis in multidrug resistance (MDR) cells. IC50 (50% inhibitory concentration) value of DOX-AcFu was lower than that of free DOX in the MDR model cells. Based on these results, we strongly suggest that AcFu nanoparticles have a promising potential for development as a one-step therapy containing agents for both immuno- and chemotherapy. (C) 2013 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available